InterOcean Capital LLC boosted its position in Stryker Co. (NYSE:SYK) by 2.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,309 shares of the medical technology company’s stock after purchasing an additional 109 shares during the period. InterOcean Capital LLC’s holdings in Stryker were worth $717,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Advisor Group Inc. lifted its holdings in Stryker by 0.9% in the 4th quarter. Advisor Group Inc. now owns 35,452 shares of the medical technology company’s stock valued at $7,445,000 after acquiring an additional 305 shares during the last quarter. Transform Wealth LLC lifted its holdings in shares of Stryker by 42.9% in the fourth quarter. Transform Wealth LLC now owns 5,020 shares of the medical technology company’s stock valued at $1,054,000 after purchasing an additional 1,507 shares in the last quarter. Raymond James & Associates lifted its holdings in shares of Stryker by 7.4% in the fourth quarter. Raymond James & Associates now owns 342,121 shares of the medical technology company’s stock valued at $71,829,000 after purchasing an additional 23,591 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc. acquired a new stake in shares of Stryker in the fourth quarter worth $340,000. Finally, Cibc Bank USA grew its holdings in shares of Stryker by 3.4% during the fourth quarter. Cibc Bank USA now owns 3,184 shares of the medical technology company’s stock valued at $668,000 after buying an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 73.07% of the company’s stock.
In other news, VP Katherine Ann Owen sold 9,149 shares of the stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $186.79, for a total value of $1,708,941.71. Following the completion of the sale, the vice president now directly owns 1,085 shares of the company’s stock, valued at $202,667.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Srikant M. Datar sold 200 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $194.32, for a total transaction of $38,864.00. Following the completion of the sale, the director now owns 17,686 shares in the company, valued at approximately $3,436,743.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,670 shares of company stock worth $2,380,526. 6.80% of the stock is currently owned by company insiders.
SYK stock traded down $0.95 during midday trading on Friday, hitting $184.14. 1,659,719 shares of the company traded hands, compared to its average volume of 1,767,916. Stryker Co. has a twelve month low of $124.54 and a twelve month high of $226.30. The stock has a market capitalization of $69.38 billion, a price-to-earnings ratio of 32.36, a price-to-earnings-growth ratio of 3.24 and a beta of 0.85. The company has a quick ratio of 1.77, a current ratio of 2.58 and a debt-to-equity ratio of 0.72. The business has a 50 day simple moving average of $180.04 and a 200-day simple moving average of $195.08.
Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $1.84 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.69 by $0.15. The business had revenue of $3.59 billion during the quarter, compared to the consensus estimate of $3.45 billion. Stryker had a net margin of 14.47% and a return on equity of 24.90%. Stryker’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.88 EPS. Equities research analysts forecast that Stryker Co. will post 6.2 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.575 per share. This represents a $2.30 dividend on an annualized basis and a yield of 1.25%. The ex-dividend date is Monday, June 29th. Stryker’s dividend payout ratio (DPR) is 27.85%.
A number of brokerages have commented on SYK. UBS Group decreased their price objective on Stryker from $230.00 to $202.00 and set a “neutral” rating for the company in a research report on Friday, May 1st. Credit Suisse Group raised their price target on shares of Stryker from $229.00 to $237.00 and gave the stock an “outperform” rating in a report on Friday, May 1st. BTIG Research reaffirmed a “buy” rating on shares of Stryker in a research report on Thursday, January 30th. Barclays lowered shares of Stryker from an “equal weight” rating to an “underweight” rating and set a $155.00 price objective on the stock. in a research note on Monday, April 13th. Finally, Wells Fargo & Co lifted their target price on shares of Stryker from $201.00 to $205.00 and gave the company an “overweight” rating in a research note on Friday, May 1st. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Stryker currently has an average rating of “Buy” and a consensus target price of $214.23.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Further Reading: How Do I Invest in Dividend Stocks
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.